The Longevity Reality Radar
46 approaches, rated by evidence.

Trametinib plus rapamycin

Trametinib + Rapamycin combination. Aging itself. Reviewed Jul 2026.

The combination extended mouse lifespan by about 27 to 29% in one study and has not been tested for aging in people.

Stage
Preclinical, mice
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
D
single mouse study
Animal or lab only, single pilot, or case reports. How grades work.

What it is

Two already-FDA-approved drugs (a cancer MEK-inhibitor plus rapamycin) combined to mimic the metabolic effects of fasting via the insulin/TOR pathway.

The evidence

Nature Aging (2025): rapamycin +17% lifespan, trametinib +10%, the combination +29% (female) / +27% (male) with reduced tumor burden and inflammation.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Aging itself

All 17 in Aging itself.

  • Rapamycin for longevityGrade C, strong animal data. Approved drug, off-label use.Extends lifespan across many animal species, but there is no human outcome data for longevity and side effects such as poor wound healing and infection are real.
  • Acarbose for longevityGrade C, strong animal data. Approved drug, off-label use.One of the most reproducible lifespan extenders in mice, mainly in males, but there is no human longevity trial.
  • VO₂max and strength for longevityGrade B, large cohorts. Established.In large observational cohorts the top VO₂max quartile has about 4 to 5 times lower all-cause mortality than the bottom, and nothing pharmacological on this list comes close.
  • RentosertibGrade C, post-hoc biomarker. Phase 3, for lung fibrosis.Six aging clocks moved in 42 lung-fibrosis patients over 12 weeks, a design that cannot separate slowed aging from a treated lung, and no healthy-volunteer or outcome data exist.
  • Senolytics (dasatinib, quercetin, fisetin)Grade C, small human studies. Phase 1/2.Small human studies show the drugs can be given, with off-target side effects, but no durable benefit in people has been shown.
  • Partial epigenetic reprogramming (ER-100)Grade D, animal data only. Phase 1, in the eye.A first-in-human safety trial in the eye has started, but every efficacy result so far comes from animals.

Guides that cover this